Stribild elvitegravir/cobicistat/emtricitabine/tenofovir regulatory update
FDA approved Gilead's Stribild to treat HIV-1 infection in treatment-naive adults. The once-daily tablet comprises elvitegravir, cobicistat and Truvada emtricitabine/tenofovir. Gilead launched Stribild last week with a wholesale acquisition cost (WAC) of about $28,500 per year. Stribild is Gilead's third approved single tablet HIV regimen - the first being Atripla emtricitabine/tenofovir/efavirenz and the second Complera emtricitabine/tenofovir/rilpivirine. The annual WAC is about $21,000 for Atripla and about $22,000 for Complera. Gilead co-markets Atripla with Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). The Tibotec Pharmaceuticals Ltd. unit of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) partnered with Gilead in 2009 to develop Complera, which is approved in the U.S. and as Eviplera in the EU to treat HIV-1 infection in treatment-naive adults. ...